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Abstract: This study explores sex differences in the outcomes of patients with schizophrenia 
(clinical/functional remission and recovery) across diverse regions of the world (Northern 
Europe, Southern Europe, Central and Eastern Europe, Latin America, East Asia, and North 
Africa and the Middle East). Data (n=16,380 for this post hoc analysis) were taken from the 
World-Schizophrenia Health Outcomes Study. In most regions, females had a later age at first 
service contact for schizophrenia, a lower level of overall/negative symptom severity, lower rates 
of alcohol/substance abuse and paid employment, and higher percentages of having a spouse/
partner and independent living. Overall, females had slightly higher rates of clinical remission 
(58.0% vs 51.8%), functional remission (22.8% vs 16.0%), and recovery (16.5% vs 16.0%) at 
36 months (P,0.001 for all). This pattern was consistently observed in Southern Europe and 
Northern Europe even after controlling for baseline sex differences, but not in other regions. 
In Central and Eastern Europe, rates of clinical remission were higher in females at 36 months, 
but those of functional remission and recovery were similar between males and females. The 
opposite was observed for Latin America. In East Asia, sex differences were rarely observed 
for these outcomes. Finally, in North Africa and the Middle East, sex differences in these 
outcomes were pronounced only in regression analyses. These regional variations shed light 
on the importance of psychosocial and cultural factors and their effects on sex in the prognosis 
of schizophrenia.
Keywords: sex, remission, recovery, region, schizophrenia, world
Introduction
Schizophrenia is a debilitating psychiatric condition, affecting ~1% of both males 
and females during their lifetime.1 However, a number of studies have suggested that 
females with schizophrenia generally have a more favorable course and outcome than 
males. They tend to have higher rates of response, remission, and recovery, lower 
rates of rehospitalization, shorter lengths of stay, longer time to relapse, and better 
social adjustment.2–9 Recent findings from the Worldwide-Schizophrenia Outpatient 
Health Outcomes (W-SOHO) study, the largest prospective observational study on 
the outcomes of schizophrenia conducted in 37 countries across diverse regions of 
the world, also highlight a better course and outcome in females.5,7 In addition, a US 
study on the course of schizophrenia and other psychotic disorders in 97 patients 
also reported better global outcomes such as improvement in psychotic activity and 
functioning in females than in males over a 20-year period.4
Several biological, psychosocial, and cultural factors have been suggested to 
explain these sex differences. These include the following tendencies in females: 
1) later onset of illness,10–13 2) fewer negative symptoms,14–19 3) a less severe form 
of illness,20 4) better premorbid functioning,21–23 5) better social functioning or social 
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acceptance,24,25 6) better response to antipsychotics,13,26 
7) lower frequency of socially undesirable behavior such 
as substance abuse and noncompliance to treatment,27,28 and 
8) the potential protective role of estrogen.29
Nevertheless, there are also some studies that have reported 
no sex differences in the outcomes of schizophrenia.30–32 
For instance, recent findings from the “cross-sectional” 
European Group on Functional Outcomes and Remission in 
Schizophrenia study conducted in 12 centers in Europe with 
276 stabilized patients with schizophrenia, schizoaffective, or 
delusional disorder indicated no sex differences in the rate of 
symptomatic and functional remission, despite the fact that 
females had a later onset of the illness, less severe negative 
symptoms, and less frequent alcohol abuse than males.31
Further research is needed to better understand the com-
plex role of sex in the prognosis of schizophrenia. A cross-
cultural comparison will be particularly important since it 
will enhance our understanding of the relative importance 
of biological and sociocultural factors on the sex differences 
in the outcomes of schizophrenia. We thus aimed to extend 
the earlier findings of the W-SOHO to assess whether a more 
favorable course of illness observed in females is stable 
across different regions of the world. The specific objectives 
of this study were twofold: 1) to describe baseline clinical 
characteristics of both males and females in each of the six 
regions studied (Northern Europe, Southern Europe, Central 
and Eastern Europe, Latin America, East Asia, and North 
Africa and the Middle East), and 2) to explore whether males 
and females have a similar disease course over a 3-year 
period in terms of clinical remission, functional remission, 
and recovery across the regions.
Methods
study design and patient sample
The Schizophrenia Outpatient Health Outcomes (SOHO) 
study was a 3-year, international, prospective, observational 
study on the outcomes of treatment with antipsychotics for 
schizophrenia. SOHO was conducted in ten Western European 
countries33 as well as in 27 countries across four continents as 
the Intercontinental SOHO.34 Data from all 37 participating 
countries have been pooled to produce the W-SOHO dataset. 
A total of 17,384 patients were included in the W-SOHO 
dataset; the details of the study are available elsewhere.35 
This study followed the ethical standards of responsible local 
committees and regulations from the participating countries 
and was conducted in accordance with the ethical principles 
of the Declaration of Helsinki. This analysis was approved 
by the Ethics Committee of Fundació Sant Joan de Déu. 
Ethical Review Board approval was also obtained from the 
participating 27 countries wherever required by local law for 
observational studies. All patients provided either verbal or 
written informed consent for the provision and collection of 
data during the observational period.
Participating psychiatrists offered enrollment to adult 
patients (at least 18 years of age) initiating or changing antip-
sychotic medication for the treatment of schizophrenia, who 
presented within the normal course of care in the outpatient set-
ting. The diagnosis of schizophrenia was made by the participat-
ing psychiatrists using standard diagnostic criteria (Diagnostic 
and Statistical Manual of Mental Disorders, fourth edition,36 or 
International Classification of Diseases, tenth edition).37
As the initial objective of SOHO was to compare the 
outcomes of patients starting olanzapine with other antipsy-
chotics, the study was designed to provide two patient cohorts 
of approximately equal size: patients starting olanzapine, 
and those starting any other antipsychotic. Importantly, the 
antipsychotic treatment prescribed to each patient was wholly 
based on the opinion of the treating psychiatrist; patients were 
asked to participate in the study after they had received their 
medication prescription. In addition, changes in medication, 
dosing, and concomitant medication were possible at any time 
during follow-up as determined by the treating psychiatrist.
Data collection
Data collection for the study occurred during routine out-
patient visits and was targeted for baseline, 3 months, and 
6 months post baseline, and every 6 months thereafter.
Clinical severity was assessed by the treating psychiatrists 
at each visit using a scale based on the Clinical Global Impres-
sions Severity Scale – Schizophrenia version (CGI-SCH),38 
which evaluates symptom severity across positive, negative, 
depressive, and cognitive subdomains as well as overall 
symptoms from 1 (normal, not ill) to 7 (extremely ill).
Other information collected at baseline or at follow-up 
visits include key demographic characteristics (eg, age, age at 
first contact, sex, and region), functional status (eg, relation-
ships, housing conditions, work status, and social activities), 
clinical status (eg, weights [kg], alcohol/substance abuse/
dependency, and suicide attempts), antipsychotic medication 
(drug name, formulation, dosage, and reasons for medication 
change if applicable), concomitant medication (anticholin-
ergics, antidepressants, anxiolytics/hypnotics, and mood 
stabilizers), adverse events (eg, extrapyramidal symptoms, 
tardive dyskinesia, sexual dysfunction), quality of life, and 
health service use (eg, hospitalization, day care visits, and 
outpatient visits).
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Regional classification and definition of 
outcomes
Regional classification
The 37 countries participating in the W-SOHO study were 
grouped into six regions as follows: Northern Europe 
(Denmark, France, Germany, Ireland, the Netherlands, and 
the UK); Southern Europe (Greece, Italy, Portugal, Spain, 
and Israel [Israel was included in the Southern Europe group 
based on ethnicity, economic and health care systems]); 
Central and Eastern Europe (Czech Republic, Hungary, 
Lithuania, Poland, Romania, Russia, Slovakia, and Slovenia); 
Latin America (Argentina, Chile, Colombia, Costa Rica, 
El Salvador, Guatemala, Honduras, Mexico, Peru, Puerto 
Rico, and Venezuela); East Asia (Korea, Malaysia, and 
Taiwan); and North Africa and the Middle East (Algeria, 
Egypt, Saudi Arabia, and Turkey).
Definition of clinical remission
Clinical remission was defined as achieving a score of 3 
(mild severity) or less on the CGI-SCH overall severity 
score, the CGI-SCH positive symptoms score, the CGI-
SCH negative symptoms score, and the CGI-SCH cognitive 
symptoms score for a period of 6 months or more (ie, at least 
two consecutive visits).39 In addition, the patient should 
not have been hospitalized during the period. Given that 
two consecutive visits were considered, clinical remission 
was defined from the 12-month visit. This definition of 
clinical remission was based on the Andreasen criteria,40 
as presented and validated in a previous report from the 
SOHO study.39
Definition of functional remission
Functional remission was defined from the 12-month visit 
as having good social functioning for a period of 6 months 
or more (ie, at least two consecutive visits). Good social 
functioning included those patients who had 1) a positive 
occupational/vocational status, ie, paid or unpaid full- or 
part-time employment, being a currently registered university 
student, or a housewife; 2) independent living; and 3) active 
social interactions, ie, having more than one social contact 
during the last 4 weeks or having a spouse or partner.
Definition of recovery
Recovery was defined from the 18-month visit as achiev-
ing functional remission at both current and previous visits 
(ie, two consecutive visits) and clinical remission at the 
current visit.
statistical analysis
A total of 16,497 patients were prescribed antipsychotic 
monotherapy at baseline. Of these, 16,380 patients who had 
non-missing data for sex (male for female) were included in 
the current analysis. Approximately two-thirds (n=10,697; 
65.3%) of these patients were available at the end of the 
study (65.0% in Northern Europe, 73.2% in Southern 
Europe, 73.6% in Central and Eastern Europe, 58.7% in Latin 
America, 39.9% in East Asia, and 53.0% in North Africa and 
the Middle East at 36 months).
Baseline characteristics of the study sample were 
described for each sex in each of the six regions. Differ-
ences in baseline characteristics between males and females 
in each region were compared using chi-square tests for 
categorical variables and Wilcoxon two-sample tests for 
continuous variables.
Rates of clinical remission, functional remission, and 
recovery were also described and compared between the 
sexes at follow-up visits in each of the six regions, using 
chi-square tests. In addition, generalized estimating equa-
tions with a logit link were used to examine the impact of 
sex on these outcomes, controlling for the following base-
line variables: CGI-SCH overall scores, age at first service 
contact for schizophrenia, duration of illness, current alcohol 
or substance abuse, hospitalization in the 6 months prior to 
baseline, independent living at baseline, having a spouse or 
partner at baseline, being socially active in the 4 weeks prior 
to baseline, having paid employment at baseline, and visits. 
The unstructured covariance pattern was used to take into 
account the within-patient correlation.
All statistical analyses were performed using the SAS 
software (version 9.3), using PROC GENMOD for binomial 
outcome variables (SAS Institute Inc., Cary, NC, USA).
Results
sex differences in the baseline patient 
characteristics across different regions
A total of 16,380 patients were included in the current analy-
sis. The number of patients (female percentages) in each of 
the six regions was n=4,086 for Northern Europe (46.6%), 
n=5,585 for Southern Europe (38.9%), n=2,024 for Central 
and Eastern Europe (52.3%), n=2,396 for Latin America 
(41.5%), n=1,179 for East Asia (50.3%), and n=1,110 for 
North Africa and the Middle East (36.9%).
Table 1 summarizes the baseline characteristics of 
the study sample by sex in each of the six regions. There 
were some differences in patient characteristics between 
the sexes as well as between the regions. The pattern of 
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sex differences was, however, generally similar across the 
regions, except for North Africa and the Middle East. For 
example, the mean age at first service contact for schizo-
phrenia was 2–4 years later in females in all regions except 
North Africa and the Middle East, where both males and 
females had their first service contact at similar mean ages 
(26.7 [standard deviation, SD =9.3] for females and 25.9 
[SD =8.1] for males, P=0.412). Clinical symptom severity 
at baseline, as measured with the CGI-SCH overall scores, 
was also lower in females in most regions, but similar 
between males and females in North Africa and the Middle 
East (P=0.122) and in Latin America (P=0.750). Notably, 
the overall severity was highest in both sexes in North 
Africa and the Middle East (4.6 [SD =1.0] for both sexes). 
Moreover, positive symptom severity was also highest in 
this region, especially for females (mean CGI-SCH positive 
symptoms score: 4.5 [SD =1.3] for females and 4.2 [SD 
=1.4] for males, P=0.002). Nevertheless, the level of nega-
tive symptom severity was similar to that in other regions, 
and all regions including North Africa and the Middle East 
exhibited a lower level of negative symptom severity in 
females than in males. Meanwhile, depressive symptom 
severity was higher in females than in males in Northern 
Europe, Southern Europe, and Latin America, but similar 
between the two in other regions. There were no sex differ-
ences in cognitive symptom severity across all regions.
The percentage of current alcohol or substance abuse 
was also generally lower in females than in males across all 
regions. As for baseline functional status, a higher percent-
age of females than males had a spouse or partner and also 
lived independently in their own homes in all regions but 
North Africa and the Middle East; the opposite pattern was 
observed in this region albeit not statistically significant 
(29.0% for females and 33.4% for males for the former, 
P=0.145; 23.5% for females and 26.9% for males for the 
latter, P=0.208). However, the percentage being socially 
active was generally similar between the sexes across the 
regions except for Southern Europe, where a higher percent-
age of males than females were socially active (61.5% for 
females and 66.3% for males, P,0.001). The percentage in 
paid employment was also generally higher in males across 
the regions, especially in East Asia (13.0% for females and 
20.2% for males, P,0.001) and North Africa and the Middle 
East (14.3% for females and 26.4% for males, P,0.001). 
Notably, the percentages for independent living and being 
socially active were generally higher for both males and 
females in Europe, especially in Northern Europe, compared 
with the other non-European regions.
sex differences in rates of clinical 
remission, functional remission, and 
recovery across different regions
Overall, a higher percentage of females than males achieved 
clinical remission, functional remission, and recovery 
throughout the follow-up, although the differences were 
relatively small. More than half of both males and females 
achieved clinical remission at 36 months (58.0% vs 51.8%, 
P,0.001), and much fewer patients (in both sexes) achieved 
functional remission (22.8% vs 16.0%, P,0.001) and recov-
ery (16.5% vs 11.7%, P,0.001) at 36 months.
Figures 1–3 show the rates of these outcomes by sex 
over the follow-up period in each of the six regions. While 
females generally achieved better outcomes than males 
across the regions, there were some inconsistencies in this 
pattern outside Europe, especially for functional remission 
and recovery. As for clinical remission (Figure 1), a higher 
percentage of females than males achieved clinical remission 
at 36 months across the regions, but the sex difference was 
not statistically significant in Latin America (P=0.633) and 
East Asia (P=0.217). In addition, the sex difference in this 
rate became statistically significant only at 36 months, but 
not at other earlier visits, in North Africa and the Middle 
East. Notably, however, the rates of clinical remission were 
generally higher in both sexes outside Europe including 
Latin America and East Asia as well as North Africa and 
the Middle East.
In contrast to clinical remission, the rates of functional 
remission were generally higher in Northern Europe and 
Southern Europe than in the other regions, and also a higher 
percentage of females than males still achieved functional 
remission in these regions and also in Latin America 
(Figure 2). While a similar pattern was observed in Central 
and Eastern Europe (17.4% for females and 14.6% for males 
at 36 months), the sex difference did not reach statistical 
significance (P=0.151). No sex difference in the rates of 
functional remission was observed in East Asia (13.3% for 
females and 15.6% for males at 36 months, P=0.479) and 
also in North Africa and the Middle East (15.9% for females 
and 15.8% for males at 36 months, P=0.969).
As for recovery (Figure 3), the pattern by sex and 
region was very similar to that of functional remission; 
the sex difference at 36 months was only statistically sig-
nificant in Northern Europe (18.6% vs 15.0%, P=0.014), 
Southern Europe (15.3% vs 7.9%, P,0.001), and Latin 
America (22.5% vs 17.0%, P=0.009), but not in Central 
and Eastern Europe (13.7% vs 11.7%, P=0.266), East 
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Asia (10.7% vs 13.5%, P=0.344), and Africa and the Middle 
East (13.0% vs 12.1%, P=0.743).
The pattern of these outcomes by sex and region was largely 
maintained even after key baseline patient characteristics were 
controlled for (Table 2). There were, however, two broad excep-
tions. First, the sex difference in achieving clinical remission 
during follow-up was statistically significant only in Southern 
Europe (odds ratio [OR] of female vs male =1.45, P,0.001) 
and North Africa and the Middle East (OR =1.36, P=0.046) at 
a significance level of 0.05, and marginally significant at a sig-
nificance level of 0.1 in Northern Europe (OR =1.15, P=0.056), 
Central and Eastern Europe (OR =1.19, P=0.057), and also in 
East Asia (OR =1.30, P=0.077). Second, unlike in the descrip-
tive statistics for functional remission and recovery, females in 
North Africa and the Middle East appeared to be more likely 
than males to achieve functional remission and recovery dur-
ing follow-up in regression analyses (OR =1.72, P=0.027 for 
functional remission; OR =1.81, P=0.022 for recovery). The 
other regions exhibited patterns of sex differences similar to 
those observed in descriptive statistics. As in clinical remis-
sion, the sex difference in achieving functional remission and 
recovery was greatest in Southern Europe (OR =2.47, P,0.001 
for functional remission; OR =1.98, P,0.001 for recovery). 
In addition, the sex difference was statistically significant in 
Northern Europe (OR =1.51, P,0.001 for functional remis-
sion; OR =1.49, P,0.001 for recovery) and Latin America 
(OR =1.52, P=0.001 for functional remission; OR =1.40, 
P=0.013 for recovery), but not in Central and Eastern Europe 
(OR =1.14, P=0.366 for functional remission; OR =1.06, 
P=0.715) and East Asia (OR =1.00, P=0.985 for functional 
remission; OR =0.94, P=0.807 for recovery).
Discussion
sex differences in the prognosis of 
schizophrenia
The results of the W-SOHO study, the largest prospective 
observational study on the outcomes of schizophrenia in the 
outpatient setting, revealed the existence of sex differences in 
the prognosis of schizophrenia, with relevant regional differ-
ences. Consistent with the prevailing evidence, females had 
a higher frequency of clinical remission (58.0% vs 51.8%), 
functional remission (22.8% vs 16.0%), and recovery (16.5% 
vs 16.0%) at 36 months than males, although the differences 
were relatively small. Remarkably however, not all regions 
followed this pattern: a better course of illness in females 
was consistently observed for all three outcomes in Southern 
Europe and Northern Europe, but not in other regions. The 
sex differences in the former regions were maintained even 
after controlling for the potential mediators for the link 
between sex and outcomes, such as age at first service con-
tact for schizophrenia, clinical severity, alcohol or substance 
abuse, and functional status at baseline.
This regional variation, despite the consistency of the 
study design and methodology in all of the participating 
countries of W-SOHO, may indicate the importance of psy-
chosocial and cultural factors and their differential effects 
on sex in the prognosis of schizophrenia. However, the 
current analysis did not explore the relative contributions 
of both biological and psychosocial/cultural factors to the 
sex differences and their interplay, which clearly warrants 
further research.
regional variation in sex differences 
in the patient characteristics and the 
prognosis of schizophrenia
As part of the World Health Organization (WHO) Collabora-
tive Study on the Assessment and Reduction of Psychiatric 
Disability conducted over 25 years ago, Hambrecht et al41 
examined and compared the influence of sex on age at onset, 
symptomatology, and course of schizophrenia in patients 
with schizophrenia, paranoid, or unspecified psychosis from 
seven Western European (n=223), Balkan (n=156), and 
Islamic centers (n=141). Some regional differences emerged: 
an earlier onset in males was observed in all five European 
Table 2 gee results: odds ratios of female vs male in achieving remission, functional remission, and recovery during follow-up in 
each region
Region Clinical remission Functional remission Recovery
OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value
Northern europe 1.15 1.00–1.32 0.056 1.51 1.26–1.80 ,0.001 1.49 1.21–1.83 ,0.001
southern europe 1.45 1.29–1.62 ,0.001 2.47 2.07–2.94 ,0.001 1.98 1.62–2.41 ,0.001
central and eastern europe 1.19 1.00–1.43 0.057 1.14 0.86–1.53 0.366 1.06 0.77–1.46 0.715
latin america 1.08 0.91–1.29 0.380 1.52 1.18–1.95 0.001 1.40 1.08–1.82 0.013
east asia 1.30 0.97–1.73 0.077 1.00 0.63–1.57 0.985 0.94 0.55–1.61 0.807
North africa and the Middle east 1.36 1.01–1.84 0.046 1.72 1.07–2.77 0.027 1.81 1.09–3.20 0.022
Abbreviations: CI, confidence interval; GEE, generalized estimating equations; OR, odds ratio.
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centers, but not in Islamic centers; similarly, sex differences 
in symptomatology were found in the former, but rarely in 
the latter. While the study did not make a cross-cultural 
comparison of sex differences in course of schizophrenia, 
the findings with the pooled sample showed that blunted 
affect, social withdrawal, alcohol abuse, and self-neglect 
were more frequent in males than in females at 1- and 2-year 
follow-ups. To our knowledge, there are no other published 
cross-national studies that have explored sex differences in 
the prognosis of schizophrenia.
The findings of W-SOHO, as mentioned previously, 
revealed some regional variation in the sex differences in 
the outcomes of schizophrenia in terms of clinical remis-
sion, functional remission, and recovery. Southern Europe 
and Northern Europe were the only regions where the sex 
differences were observed for all three outcomes in both 
descriptive and regression analyses, with higher rates of these 
outcomes in females than in males. Consistent with previ-
ous reports, females in these regions exhibited the following 
tendency, which might have contributed to higher rates of 
remission and recovery in females: a later age at first service 
contact for schizophrenia, a lower level of overall clinical 
severity, a lower level of negative symptom severity (but a 
higher level of depressive symptom severity), a lower per-
centage of alcohol or substance abuse at baseline, a higher 
percentage of having a spouse or partner, and a higher per-
centage of independent living. While similar patterns were 
also observed in other regions albeit with some exceptions, 
especially for North Africa and the Middle East, the mean 
age at first service contact, the percentage of independent 
living, and that of being socially active were generally higher 
in both males and females in Europe, compared to the other 
non-European regions. Notably, the sex differences in the 
rates of remission/recovery found in Southern and Northern 
Europe were not fully accounted for by the sex differences 
in these baseline patient characteristics.
The sex differences in the outcomes of schizophrenia 
were less pronounced and consistent in the other regions. 
For instance, in Central and Eastern Europe, rates of clinical 
remission were higher in females than in males at 36 months, 
but those of both functional remission and recovery were 
similar between males and females. On the contrary, in Latin 
America, the former was similar between males and females, 
but the latter rates were higher in females than in males.
In addition, sex differences in the outcomes of schizo-
phrenia were rarely observed in East Asia (composed of 
Malaysia, South Korea, and Taiwan in this study). This 
finding does not seem consistent with the view that marriage 
can act as a protection against psychological breakdowns, 
given the fact that the rate of marriage was highest in East 
Asian females (56.4%) across both sexes of all regions. 
There is, however, some evidence suggesting an increased 
risk of suicide in young married females in South Korea42 
and Taiwan.43 Taken together, this may indicate no protective 
role of marriage in females against psychological breakdowns 
in this region where the role of females is changing fast. 
Moreover, the rate of paid employment was also lowest in 
these East Asian females, and unlike other regions, there was 
no sex difference in the rate of alcohol or substance abuse in 
this region (1.3% for females vs 2.0% for males, P=0.353). 
All of these might have diluted the sex differences in the 
outcomes of schizophrenia in this region, and also contributed 
to the lowest frequency of functional remission and recovery 
in East Asian females.
Finally, North Africa and the Middle East revealed some 
interesting patterns. First of all, there were no sex differences 
in the age at first service contact for schizophrenia (26.7 [SD 
=9.3] for females vs 25.9 [SD =8.1] for males, P=0.412) and 
in the percentage of having a spouse or partner (29.0% for 
females vs 33.4% for males, P=0.145). An earlier age at first 
service contact in males by 2–4 years was a phenomenon 
observed in all other regions. Nevertheless, this finding, ie, no 
sex difference in the age at first service contact in this region, 
is consistent with the earlier WHO Collaborative Study on the 
Assessment and Reduction of Psychiatric Disability, which 
also showed no sex difference in the onset of schizophre-
nia in Islamic centers but not in other European centers.41 
Notably, the level of positive symptoms, as measured with the 
CGI-SCH positive symptoms scores, was higher in females 
than in males in this region (4.5 [SD =1.3] vs 4.2 [SD =1.4], 
P=0.002), but similar between the two in other regions. In 
fact, the level of positive symptom severity was highest in this 
group of females across both sexes of all regions. It should 
also be noted that the level of overall symptom severity 
was also highest in both males (4.6 [SD =1.0]) and females 
(4.6 [SD =1.0]) in this region than in anywhere else. This may 
indicate that only those patients with more severe symptoms 
are likely to be diagnosed and treated for schizophrenia in 
North Africa and the Middle East. The role of positive symp-
toms in this sense might be particularly more important in this 
region, especially for females. No sex difference observed 
in the percentage of having a spouse/partner, unlike in other 
regions, may also be related to Islamic culture. Remarkably, 
this region showed a better course of illness in females than 
in males for all three outcomes only after controlling for the 
baseline patient characteristics. Otherwise, females had a 
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greater frequency only for clinical remission at 36 months 
but neither at other earlier visits nor for other outcomes 
(ie, functional remission and recovery) at any visits.
These regional variations are likely to indicate the influ-
ence of biological, psychosocial, and cultural factors and 
their differential effects on sex in the course of schizophrenia. 
Among the biological factors, there may exist a protective 
role of estrogen.29 Our study was, however, unable to test this 
hypothesis since its plasma level of estrogen was not exam-
ined in this observational study. Moreover, given that age at 
first service contact for schizophrenia and duration of illness 
were taken into account in our regression analyses, patient age 
was not controlled for as a separate variable in the analyses. 
The literature suggests that better outcomes of females with 
schizophrenia may decline over time, and eventually approxi-
mate that of males with schizophrenia due to a reduction in 
the level of estrogen in females.44–46 However, Grossman et al4 
did not find this pattern in a 20-year follow-up of patients 
with schizophrenia. In addition, although a shorter duration 
of illness was significantly associated with better outcomes 
across the regions in our study, similar associations were 
observed for both males and females (data not shown).
In summary, we found sex differences in the course of 
schizophrenia which were more marked in Europe. Continents 
that for cultural or religious differences have more marked 
sex inequalities did not show sex differences with a more 
favorable course in females. In these countries with higher 
sex inequality, the more favorable course in females, which is 
probably due to the protective role of estrogen, might have been 
diluted given the social situation of females. A recent study 
by Luhrmann et al47 suggests that the clinical presentation of 
schizophrenia may be the result of an interaction between the 
pathological and cultural processes, a process which they name 
“social kindling”. Accordingly, sex differences will arise from 
the complex interactions among very different biological and 
environmental factors. However, since that study is descriptive, 
we cannot test the hypothesis that the lack of sex differences 
in these areas is due to cultural or religious factors.
Taken together, these findings also highlight the need for 
a more sex-sensitive approach in the treatment of schizophre-
nia. Moreover, psychosocial and cultural factors should also 
be fully taken into account, in addition to biological factors, 
in order to optimize both clinical and functional outcomes 
in schizophrenia.
limitations
The current findings need to be interpreted in the context of 
the following limitations of the study. First, the W-SOHO 
studies were originally designed to assess the comparative 
costs and outcomes associated with treatment. The current 
findings as such emerged only from secondary analyses 
formulated to test sex differences in the outcomes of schizo-
phrenia across diverse regions of the world. Second, the 
37 countries included in the W-SOHO study were categorized 
into six regions, but they may not be representative of these 
regions and also had different sample sizes. Third, the sex 
differences in the outcomes of schizophrenia in each of the 
six regions were adjusted for clinical and sociodemographic 
characteristics of patients. However, data constraints on 
biological factors such as a family history of schizophrenia 
or plasma level of estrogen limited our ability to fully dis-
tinguish the influence of psychosocial and cultural factors 
from that of biological factors on the sex differences in the 
prognosis of schizophrenia. In addition, there could be other 
unobserved differences between the sexes and between the 
regional cohorts, which could confound our results. Fourth, 
we have not analyzed the role that differences in antipsy-
chotic treatment response may have in these findings. Fifth, 
although there were no relevant differences in follow-up 
rate between males and females, there were some among the 
regions, with a higher dropout rate in Asia, Africa, and the 
Middle East.5 Notably, these regions also had the lowest per-
centage of females participating in the study, and the severity 
of their cases was higher than the rest of the regions. This 
could be related to only the most severe cases being treated in 
those countries. If that is the case, this could partially explain 
the lack of sex differences: the less severe cases (especially 
for females) could have an even better preclinical outcome 
and do not enter in the study. In summary, there could be 
a number of unobserved differences between the sexes and 
between the regional cohorts that could confound our results. 
Finally, our definition of clinical remission required a low 
level of symptoms for at least 6 months, consistent with 
the definition proposed by Andreasen et al.40 However, our 
definition of remission was based on the CGI-SCH, which 
is a valid but less specific measure of clinical severity than 
other scales such as the Positive and Negative Syndrome 
Scale.48 Previous analyses have shown a good agreement 
between this and Andreasen’s definition.49
Conclusion
The results of the W-SOHO study suggest sex differences 
in the patient characteristics and also in the outcomes of 
schizophrenia across diverse regions of the world. Con-
sistent with previous findings, a later age at first service 
contact for schizophrenia, a lower level of overall/negative 
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symptom severity, lower percentages of alcohol/substance 
abuse and paid employment, and higher percentages of hav-
ing a spouse/partner and independent living in females were 
observed in most regions, but with some exceptions. Over-
all, females had slightly higher rates of clinical remission 
(58.0% vs 51.8%), functional remission (22.8% vs 16.0%), 
and recovery (16.5% vs 16.0%) than males at 36 months. 
This pattern was consistently observed in Southern Europe 
and Northern Europe even after controlling for the baseline 
sex differences, but not in other regions. These regional 
variations shed light on the importance of psychosocial and 
cultural factors and their differential effects on sex in the 
prognosis of schizophrenia. A more sex-sensitive approach 
relevant to each culture is required in the treatment of 
schizophrenia.
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